CORRECTION Open Access

## Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis



Paul Emery<sup>1\*</sup>, Yoshiya Tanaka<sup>2</sup>, Tracy Cardillo<sup>3</sup>, Douglas Schlichting<sup>3</sup>, Terence Rooney<sup>3</sup>, Scott Beattie<sup>3</sup>, Cameron Helt<sup>3</sup> and Josef S. Smolen<sup>4</sup>

## Correction to: Arthritis Research & Therapy (2020) 22: 115 https://doi.org/10.1186/s13075-020-02199-8

Following publication of the original article [1], the authors identified errors in Fig. 1. The legends in Fig. 1c and d refer to placebo, baricitinib 4-mg and adalimumab treatment groups; the legends should refer to placebo, baricitinib 2-mg, and baricitinib 4-mg and the reference to these two studies in the figure caption are reversed. Additionally, the total number of interruptions for baricitinib 4-mg in RA-BEAM (Fig. 1b) has been corrected from 82 to 62 and the title for RA-BEAM has been corrected from 0-52 weeks to 0-24 weeks; labels have been corrected for MTX (8–14 days) in RA-BEGIN from 28 to 29 and for placebo (15–21 days) in RA-BUILD from 17 to 16.

The corrected Fig. 1 is given below.

## **Author details**

<sup>1</sup>Leeds Muscoloskeletal Biomedical Research Centre/Chapel Allerton Hospital, Chapeltown Rd, Leeds LS7 4SA, UK. <sup>2</sup>The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. <sup>3</sup>Eli Lilly and Company, Indianapolis, IN, USA. <sup>4</sup>Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.

Published online: 02 July 2020

## Reference

 Emery P, Tanaka Y, Cardillo T, et al. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22:115. https://doi.org/10. 1186/s13075-020-02199-8.

The original article can be found online at https://doi.org/10.1186/s13075-020-02199-8.


Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>\*</sup> Correspondence: P.Emery@leeds.ac.uk

<sup>&</sup>lt;sup>1</sup>Leeds Muscoloskeletal Biomedical Research Centre/Chapel Allerton Hospital, Chapeltown Rd. Leeds LS7 4SA. UK



**Fig. 1** Duration of interruptions in the phase 3 studies RA-BEGIN (**a**), RA-BEAM (**b**), RA-BEACON (**c**), and RA-BUILD (**d**)<sup>a,b</sup>. <sup>a</sup>Interruptions are based on daily tablet baricitinib study drug, including in non-baricitinib groups, which represent interruptions of the matching placebo for baricitinib. <sup>b</sup>Temporary interruption is defined as a temporary withholding of study drug that is followed by resumption of study drug during the study. MTX, methotrexate